Abstract
Address for Correspondence: Uzm. Dr. Havva Yeşil Çınkır Ankara Onkoloji Hastanesi, Tıbbi Onkoloji Bölümü Ankara - Türkiye e-mail: doctoryesil82@yahoo.com Available at www.actaoncologicaturcica.com
References
- Armstrong D, Bundy B, Wenzel L, et al. Intraperitoneal Cisplatin and Paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.
- Landrum LM, Gold MA, Moore KN, Myers TK, McMeekin DS, Walker JL. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol Oncol. 2008;108:342-7
- Zeimet AG, Reimer D, Radl AC, et al. Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer. Anticancer Res. 2009;29:2803-8.
Abstract
chemotherapy showed 16-month OS advantage for optimally resected stage III EOC (1). However, catheter-related complications are common reasons (13-40%) for discontinuation of IP treatment. These are abdominal pain, bleeding, blockage, leakage, movement, malfunction, and/or access problems (2). Peritoneovaginal fistula is a rare complication of IP treatment, “leaky vaginal cuff” was the reason for discontinuation of treatment 2 of the 71 patients in a study (3). Although the significant improvement on survival, IP chemotherapy should be given carefully
References
- Armstrong D, Bundy B, Wenzel L, et al. Intraperitoneal Cisplatin and Paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.
- Landrum LM, Gold MA, Moore KN, Myers TK, McMeekin DS, Walker JL. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol Oncol. 2008;108:342-7
- Zeimet AG, Reimer D, Radl AC, et al. Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer. Anticancer Res. 2009;29:2803-8.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Articles |
| Authors | |
| Publication Date | August 21, 2014 |
| Published in Issue | Year 2014 Volume: 47 Issue: 1 |